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doi:10.101Superior Graft-versus-Leukemia Effect Associated
with Transplantation of Haploidentical Compared with
HLA-Identical Sibling Donor Grafts for High-Risk Acute
Leukemia: An Historic Comparison
Yu Wang, Dai-Hong Liu, Lan-Ping Xu, Kai-Yan Liu, Huan Chen, Yu-Hong Chen, Wei Han,
Hong-Xia Shi, Xiao-Jun HuangThe outcomes of an historic comparison of 117 consecutive, high-risk, acute leukemia patients undergoing he-
matopoietic stem cell transplantation (HSCT) from HLA-mismatched/haploidentical donors (HID, n 5 81) or
HLA-identical sibling donors (ISD, n5 36)without the useof in vitroT cell depletion (TCD), between the period
of January 2005 and April 2009 were compared. Full engraftment was achieved in 98% of patients in the HID
group and 97% in the ISD group. The cumulative incidences of grades II–IV acute graft-versus-host disease
(aGVHD) in the HID and ISD cohorts were 49% and 24%, respectively (P 5 .014) with a relative risk (RR) of
2.99 (1.25-7.21) (P5 .014). The incidence of chronic GVHD (cGVHD) did not differ significantly between the
2 cohorts. The 2-year cumulative incidence of relapse was significantly lower in HID (26%) than in ISD patients
(49%) (P5.008). The 2-year cumulative incidence of nonrelapse mortality (NRM) was comparable in recipients
of HID (34%) and ISD grafts (38%) (P5.85). The 3-year probability of overall survival (OS) was higher in HID
patients (42%) than in ISD (20%) (P 5 .048) patients. Our comparisons suggest that HID transplants can
achieve a stronger graft-versus-leukemia (GVL) effect than ISD for high-risk acute leukemia patients.
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Hematopoietic stem cell transplantation (HSCT)
is 1 of the best, and sometimes the only, option for
the treatment of leukemia, particularly for patients
with high-risk leukemia. It is widely known that the
relapse rate of allogeneic HSCT (allo-HSCT) is lower
than that of auto- or syngeneic HSCT. Immune cells
derived from the donor contribute to the eradication
of leukemia after allo-HSCT, whereas auto- or synge-
neic HSCT have no graft-versus-leukemia (GVL)
effect. The GVL effect is usually identified in retro-
spective analyses of relapse rates following HSCT
fromhuman leukocyte antigen (HLA)-identical sibling
donors for leukemia [1] and has subsequently been
extensively confirmed in other transplant settings.ekingUniversity People’sHospital, Institute ofHematol-
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6/j.bbmt.2010.08.023Kanda et al. [2] reported that the incidence of relapse
was dramatically decreased with 1-locus–mismatched
family member HSCT compared to matched HSCT
for high-risk diseases (19% versus 47%; P 5 .004).
Reports from IBMTR also showed that in acute
leukemia, relapse risk was lower after alternative-
donor compared with HLA-identical sibling trans-
plants. This difference was statistically significant
(P \ .05) for 2-HLA-antigen–mismatched related
and HLA-antigen–mismatched unrelated donors [3].
Great progress has been made in haploidentical
donor (HID) HSCT over the past 20 years, and it
has become a feasible option for leukemia patients
especially with high-risk features without a HLA-
identical sibling donor (ISD). It has been speculated
that HID HSCT may potentially exert a strong GVL
effect. However, comparative clinical studies to con-
firm the potential beneficial GVL effects are lacking.
One possible reason for the lack of such studies is
that most HID HSCT is performed with an in vitro
T cell depletion (TCD) modality [4-13]. The lack of
a rapid donor T cell recovery secondary to profound
graft TCD limits the overall antileukemia potential
of the TCD modality compared with alternative
T cell–replete options.821
822 Biol Blood Marrow Transplant 17:821-830, 2011Y. Wang et al.Recently, we developed a new method for HLA-
mismatched/haploidentical transplantation without in
vitro TCD. The strategy comprises sequential, in
vivo modulation of the recipient and donor T cell
functions and the determination of the dose of donor
hematopoietic stem cells using the GIAC protocol
(G, donor treatment with recombinant granulocyte
colony-stimulating factor [rhG-CSF]; I, intensified
immunological suppression; A, antihuman thymocyte
immunoglobulin [ATG] for the prevention of
graft-versus-host disease [GVHD]; C, combination of
peripheral blood stem cell transplantation [PBSCT],
and bone marrow transplantation [BMT]) [14]. Using
this protocol, promising results for HID HSCT
without in vitro TCD have been achieved at our insti-
tute [14-16].WhetherHIDHSCThas a strongerGVL
effect is under consideration under our new transplant
protocol. The purpose of this nonrandomized, single-
center, retrospective study was to comparatively ana-
lyze transplantation outcomes in a consecutive series
of high-risk acute leukemia patients who underwent
HSCT from either HID or ISD without in vitro
TCD at our institute.MATERIALS AND METHODS
Patient Eligibility
Consecutive patients with high-risk acute leuke-
mia (n 5 117) receiving HSCT from either ISD (n 5
36) or HID (n 5 81) between January 2005 and April
2009 were enrolled. Patients receiving HSCT as a sec-
ond transplant following relapse after a first auto- or
allogeneic transplantation were excluded. Thirty of
the 81 high-risk acute leukemia patients from the
HID cohort were previously reported in 2009 [16],
and 19 of those 30 patients were previously reported
in another report in 2009 as well [15]; additionally, 1
of those 19 patients was previously reported in 2006
[14]. All these patients reported before were enrolled
and further followed in this study. The protocols
were approved by the institutional review board of
the Peking University Institute of Hematology, and
all patients and their donors signed consent forms. Pa-
tients in complete remission (CR)3 or beyond (patients
in CR2 were classified as intermediate risk in most
studies), nonremission, or CR1 with poor-risk cytoge-
netic abnormalities were classified as high risk. For
patients with acute myelogenous leukemia (AML),
poor-risk cytogenetic abnormalities included t(9;22)
1 other, –5 or del(5) 1 other, –7 or del(7) only, –7
or del(7) 1 other, del(11) only, del(11) 1 other [17].
For patients with acute lymphoblastic leukemia
(ALL), poor-risk cytogenetic abnormalities included
t(4;11), t(9;22), or t(8;14). A small proportion of
patients were evaluated for the Flt3 internal tandem
duplication (patients undergoing HSCT after year2008), so this part of the information was not provided
in this study. Characteristics of the patients and donors
are summarized in Table 1.
Donor Selection
A human leukocyte antigen (HLA)-matched
sibling donor was the first choice for allo-HSCT. If
a matched sibling donor was unavailable as a first treat-
ment option, patients without a suitable closely HLA-
matched unrelated donor, that is, with more than 8 of
10 matching HLA-A, B, C, DR, and DQ loci and at
least 5 of 6matchingHLA-A, B, andDR loci, or whose
disease status left insufficient time for an unrelated
donor search, were eligible for HID HSCT. To
determine HLA-A and HLA-B status, low-resolution
DNA techniques were used. High-resolution tech-
niques were used for HLA-DRB1 typing. All donor-
recipient pairs were typed at the HLA-A, B, and DR
loci at our institute. Patients who had undergone an
unrelated donor search were typed at the HLA-A, B,
C, DR, and DQ loci in China at an unrelated marrow
bank. Thirty-six sibling donor-recipient pairs were
fully HLA matched at the HLA-A, B, and DR loci.
For the other 81 donor-recipient pairs, each patient
received stem cells from a family member who shared
1HLAhaplotypewith the patient but differed to a vari-
able degree for the HLA-A, B, and D antigens of
the haplotype not shared. Apart from each donor-
recipient pair, HLA typing was done for parents and
offspring to be strictly analyzed to guarantee true
haploid genetic background. The HLA disparities in
the mismatched cohort are shown in Table 1.
Conditioning Regimen
The conditioning therapy for the HID group
was modified BUCY2 plus ATG (thymoglobulin)
consisting of cytarabine (4 g/m2/day) intravenously
on days –10 to –9; busulfan (4 mg/kg/day) orally on
days –8 to –6 before January 2008, and busulfan (3.2
mg/kg/day) intravenously on days –8 to –6 after Janu-
ary 2008; cyclophosphamide (1.8 g/m2/day) intrave-
nously on days –5 to –4; Me-CCNU (250 mg/m2)
orally once on day –3; and ATG (thymoglobulin, 2.5
mg/kg/day; Sang Stat, Lyon, France) intravenously
on days –5 to –2. Patients in the ISD group received
hydroxycarbamide (80 mg/kg) orally on day –10 and
a lower dose of cytarabine (2 g/m2/day) on day –9,
but otherwise, an identical regimen to the HLA-
mismatched patients without ATG.
GVHD Prophylaxis
All patients received cyclosporine A (CSA), myco-
phenolate mofetil (MMF), and short-term methotrex-
ate (MTX) for GVHD prophylaxis [15]. On day 11,
MTX (15 mg/m2) was administered intravenously fol-
lowed by administration at 10 mg/m2 on days 13 and
Table 1. Characteristics of Patients and Grafts
Characteristics ISD n 5 36 HID n 5 81 P *
Age, years, median (range) 41 (15-56) 29 (5-50) .001
Gender, no. (%) .25
Male 27 (75) 52 (64)
Female 9 (25) 29 (36)
Diagnosis, no. (%) .12
Acute myeloid leukemia 20 (56) 30 (37)
CR3 or beyond 5 2
Nonremission 15 28
Acute lymphoid leukemia 16 (44) 51 (63)
PH negative 3 (8) 16 (20)
CR3 or beyond 2 0
Nonremission 1 16
PH positive 13 (36) 35 (43)
Duration from diagnosis to HSCT, mo .66
Median (range) 6.0 (2.5-180) 6.3 (1-219)
Donor-patient sex matched, no. (%) .65
FM 10 (28) 24 (30)
FF 6 (17) 20 (24)
MM 17 (47) 29 (36)
MF 3 (8) 8 (10)
No. of HLA-A,-B,-DR mismatched, no. (%) —
0 36 (100) 0
1 7 (8)
2 20 (25)
3 54 (67)
Graft type, no. (%) .001
Bone marrow + peripheral blood cell 19 (53) 71 (88)
Peripheral blood cell 17 (47) 10 (12)
Median MNCs, 108/kg (range) 6.8 (4.0-14) 7.1 (3.6-11) .11
Median CD34+ count, 106/kg (range) 2.5 (1.1-3.6) 2.9 (1.5-6.2) .61
Median CD3+ count, 108/kg (range) 1.9 (0.7-3.9) 1.8 (0.9-7.4) .71
Follow-up time, months .21
Median (range) 11 (0.6-46) 16 (0.8-59)
Follow-up time in survivors, months .98
No. of evaluable patients 10 41
Median (range) 23 (10-46) 22 (11-59)
MNC indicates mononuclear cell; HSCT, hematopoietic stem cell transplantation; ISD, identical sibling donors; HID, haploidentical donors; CR, complete
remission; —, data not comparable.
*The chi-square test was used for categorical variables; the Mann-Whitney U-test was used for continuous variables.
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111 after HID HSCT. MMF was discontinued
upon engraftment after ISD HSCT, whereas in HID
patients, MMF was tapered from 1 g/day to 0.5 g/
day on day 30 and was discontinued over days 45 to
60 based on the presence or absence of severe
GVHD, infectious diseases, and relapse risk.Collection of Hematopoietic Cells
Donors were primed with rhG-CSF (Filgrastim,
Kirin, Japan; 5 mg/kg per day) injected subcutaneously
for 5 to 6 consecutive days. On the fourth day, bone
marrow (G-BM) cells were harvested. The target
mononuclear cell (MNC) count was 2  108$kg21 of
the recipient weight. In instances of major ABO blood
group incompatibility, red blood cells were removed
from bonemarrow cells by density gradient sedimenta-
tion with Hespan (B. Braun Medical Inc, Irvine, CA),
according to the manufacturer’s instructions. On the
fifth day (and sixth day if needed, that is, if target
MNC was not reached on the fifth day), peripheral
blood cells (G-PB) were collected with a COBE Blood
Cell Separator (Spectra LRS, COBE BCT, Inc., Lake-wood, CO) at a rate of 80 mL/min from a total blood
volume of 10 L. The target MNC count was 3 
108$kg21 of the recipientweight. Patientswho received
only G-PB received 2 days of leukapheresis collections
from their donors on the fourth and fifth days. The tar-
get MNC count was 5  108$kg21 of the recipient
weight. Greater than 6  108 MNC/kg or 4  106
CD341 cells/kg were planned for harvest. The extra
harvested cells were cryopreserved with dimethyl sulf-
oxide in a nitrogen tank. Data on the composition of
grafts are shown in Table 1.Prevention and Treatment of Relapse
Modified donor lymphocyte infusion (DLI) was
planned from days 45 to 120 after transplantation in
patients when no GVHD occurred or, if CSA was
tapered or stopped, GVHD was controlled. Before
DLI, serious infection must be cleared and no serious
organ failure can be present. The modified DLI regi-
men comprised G-CSF-primed PBSCs instead of har-
vested nonprimed donor lymphocytes and short-term
immunosuppressive agents [18]. Lymphocytes were
obtained from cryo-preserved G-CSF mobilized
824 Biol Blood Marrow Transplant 17:821-830, 2011Y. Wang et al.peripheral blood (G-PB) (described previously in the
section entitled ‘‘collection of hematopoietic cells’’).
For patients receiving DLI before day 90 posttrans-
plantation, the original CSA treatment was continued
for another 2 weeks after the infusion, and then tapered
and discontinued within 4 weeks if no DLI-associated
GVHD occurred. For patients receiving DLI after day
90, immunosuppression was discontinued for a mini-
mum of 2 weeks and, if no active GVHD was present,
before DLI. These patients took oral CSA or metho-
trexate (MTX, at a dose of 10 mg, repeated at day 8
after the first dose and then at a weekly interval), for
2 to 4 weeks after DLI for the prevention of DLI-
associated GVHD. The median number of CD341
cells infused was 0.59 (0.05-2.2) 106/kg. The median
number of CD31 cells infused was 0.55 (0.3-1.5) 
108/kg. Twenty-one patients (26%) in the HID group
and 17 patients (47%) in the ISD group received pro-
phylactic DLI. Reasons for not giving prophylactic
DLI in the HID cohort were as follows: graft failure
(n 5 2), GVHD (n 5 9), infection not controlled
within 120 days (n 5 3), early relapse (n 5 4), death
within 45 days (n 5 3), disagreement (n 5 9), and
the remaining 30 were Ph1-ALL patients. Reasons
for not giving prophylactic DLI in the ISD cohort
were as follows: GVHD (n 5 3), infection (n 5 2),
early relapse (n 5 3), early death (n 5 1), and the
remaining 10 were PH1-ALL patients.
When hematologic or cytogenetic relapse was di-
agnosed after HCT, the relapse was treated with a trial
phase of immunosuppressant withdrawal followed by
therapeutic DLI. Patients whose blast count in the
bone marrow at the time of post-HSCT relapse was
over 20% had received prior chemotherapy [19].
DLI was given 48 hous after the last chemotherapy
dose. For patients whose blast count was less than
20%, DLI was given without chemotherapy after
immunosuppression had been discontinued for a mini-
mum of 2 weeks and no evidence of active GVHD was
present. G-CSF-primed peripheral blood stem cells
(GPBSC) were used instead of steady donor lympho-
cyte harvests [20]. The median number of infused
CD341 cells was 2.69 (0.82-9.69)  106/kg. The
median number of infused CD31 cells was 2.09
(0.84-5.6)  108/kg. All patients received short-term
immunosuppressive agents for 2 to 4 weeks for the
prevention of DLI-associated GVHD.Therapy of DLI-Mediated GVHD
For acute GVHD (aGVHD) after MTX or CSA as
prophylaxis regimens, methylprednisolone (MP) is the
best initial therapy. Prednisone and CSA are consid-
ered as the first-line therapy for patients with chronic
GVHD (cGVHD). Other therapeutic options for
aGVHD or cGVHD are MMF, tacrolimus (FK506),azathioprine, thalidomide, monoclonal antibodies
directed against CD3 and CD25, and MTX.
Imatinibmesylatewasplanned tobeadministered to
Ph1-ALL patients without serious infection, GVHD,
or organ failure from engraftment for 3 to 6 months if
the absolute neutrophil count (ANC) remained above
1.0  109/L and the platelet count remained above
50 109/L before administration. Daily dosing of ima-
tinibwas initiated at 400mg/m2 for adults or 260mg/m2
for children. Nineteen patients in the HID group (54%
of Ph1-ALL patients) and 7 patients in the ISD group
(54%of Ph1-ALL patients) received prophylactic ima-
tinib mesylate. Reasons for not giving prophylactic
imatinib in the HID cohort were as follows: GVHD
(n5 4), infection not controlledwithin 120 days (n5 4),
death within 45 days (n5 3), and disagreement (n5 6).
Reasons for not giving prophylactic imatinib in the
ISD cohort were as follows: graft failure (n 5 1),
GVHD (n 5 1), infection not controlled within 120
days (n5 3), and disagreement (n5 1).
Ph1-ALL patients who experienced a cytogenetic
or hematologic relapse after HSCT and patients who
demonstrated rising levels (1 log increase) of bcr/abl
RNA transcripts by real-time quantitative PCR (RQ-
PCR) were given Imatinib for therapeutic use.
Definitions and Assessments
Neutrophil engraftment was defined as an ANC of
0.5 109/L ormore for 3 consecutive days, and platelet
engraftment was defined as 20  109/L or more for 7
consecutive days without transfusion. Primary engraft-
ment failure was defined as the absence of donor-
derived myeloid cells at day 60 in patients surviving
beyond day 28 after transplantation or as the need
for a second allogeneic transplant or reconstitution
with autologous cells. Chimerism was determined by
at least 2 of the following 3 methods: DNA-based
HLA typing, polymerase chain reaction (PCR) DNA
fingerprinting of short tandem repeats on recipient
PB cells, and chromosomal fluorescence in situ hybrid-
ization (FISH)on recipientBMcells. AcuteGVHDand
cGVHD were defined according to published criteria
[21,22]. Relapse was defined by morphologic evidence
of disease in the peripheral blood, marrow, or
extramedullary sites or by the recurrence and
sustained presence of pretransplantation chromosomal
abnormalities. Patients showing MRD (eg, the
presence of bcr/abl RNA transcripts by PCR) were
not classified as having relapsed. Leukemia-free survival
(LFS) was defined as survival in CR at last follow-up.
Statistical Analysis
Cumulative incidences were estimated for engraft-
ment, GVHD, nonrelapse mortality (NRM), and re-
lapse to accommodate competing risks. Competing
risks for engraftment was death without engraftment;
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relapse, and graft rejection; relapse was a competing
risk for NRM, and NRM was a competing risk for re-
lapse. For all of our study population (with or without
DLI), time to GVHD was defined as the time from
HSCT to the onset of any grade of GVHD; aGVHD
was censored at day 100 after HSCT and cGVHD
was censored at last follow-up. Associations between
graft type and outcome were evaluated using an add-
on package for the R statistical software, which allows
for the estimation of the semiparametric proportional
hazards model for the subdistribution of a competing
risk analysis as proposed by Fine and Gray [23]. In ad-
dition to the hematopoietic stem cell source, the fol-
lowing variables were considered as covariates:
recipient age, recipient and donor sex, degree of ABO
matching, graft source, disease type, time from diagno-
sis to transplantation, and dose of nucleated cells in-
fused. When groups were compared according to
continuous covariates, Mann-Whitney U-tests were
used. A chi-square test was used to compare categorical
covariates. The probability of survival was calculated
using theKaplan-Meiermethod.Todetect possible in-
fluences of allogeneic transplantation on leukemia re-
lapse in association with and independent of GVHD
(acute or chronic), patients with engraftment were cat-
egorized into 2 groups: with aGVHD or without
aGVHD (until day 100 after HSCT or until last
follow-up for patients not surviving beyond day 100 af-
terHSCT). Patients that survived longer than 100 days
after HSCT were categorized into 2 groups: with
cGVHD or without cGVHD (until final follow-up).
For each group, associations between graft type and
leukemia relapse were evaluated using cumulative inci-
dences to accommodate competing risks for NRM.
The 95% confidence interval (95% CI) was calculated
to compute the standard error. SAS version 8.2 (SAS
Institute, Cary, NC) and S Plus 2000 (Mathsoft, Seat-
tle, WA) were used for most analyses. Endpoints were
calculated at last contact, with the date of the latest
follow-up being March 1, 2010.RESULTS
Engraftment
After myeloid recovery, 2 patients died before day
28 posttransplantation. Among the patients surviving
beyond day 28, analyses of chimerism indicated that
78 out of 80 (98%) patients in the HID group and 34
out of 35 (97%) patients in the ISD group achieved
full donor chimerism by day 30 after HSCT. The
cumulative 30-day myeloid engraftment probabilities
were 98.7% in the HID cohort and 97.2% in the
ISD group (P 5 .08). Patients engrafted to absolute
neutrophil counts exceeding 0.5  109/L in a median
time of 13 days (range: 9-29 days) in the HID groupand 16 days (range: 11-25 days) in the ISD group
(P 5 .061).
Three patients (2 HID, another ISD) had primary
graft failure. All 3 received G-PB as the graft source.
One HID patient received a second HSCT with
G-BM 1 G-PB from the same donor on day 29 after
conditioning with cyclophosphamide (CTX 1000
mg/day  2), fludarabine (fludarabine 50 mg/day 
4), and anti-CD25 monoclonal antibodies (MoAb).
Despite the peak white blood cell count (WBC) of
0.9 109/L on day 32 after the second HSCT, no sus-
tained myeloid engraftment was confirmed until he
died of sepsis on day 41 after the second HSCT. The
other HID patient experienced graft failure on day
17 after 2 days of transient ANC.0.5 109/L. She re-
ceived G-BM1G-PB cells from the same donor after
anti-CD25 MoAb preparation and achieved sustain
engraftment again on day 12 after the second HSCT.
The ISD patient gave up treatment on day 28 without
engraftment and died of severe infection on day 40 af-
ter transplantation. No patients had secondary graft
failure.
Seventy-three (90%) and 31 (86%) patients
achieved platelet engraftments in the HID and ISD
groups, respectively. The 50-day cumulative platelet
engraftment probability was 86% in the HID cohort
and 83% in the ISD group (P 5 .66). These platelet
engraftments occurred at 15 days (range: 7-74 days)
and 15 days (range: 7-100 days) for the HID and ISD
patients, respectively (P 5 .66).
GVHD
At day 100 after transplantation, the cumulative
incidences of grade II–IV aGVHD in the HID and
ISD cohorts were 49% (CI, 37%-61%) and 24% (CI,
9%-41%), respectively (P 5 .014; Figure 1A), with
a relative risk (RR) of 2.99 (1.25-7.21) (P 5 .014;
Table 2). The cumulative incidences of grade III–IV
aGVHD in the HID and ISD cohorts were 15% (CI,
5%-25%) and 4% (CI, 1%-7%), respectively (P5 .13).
Sixty-nine patients in the HID cohort and 28
patients in the ISD cohort survived longer than 100
days after HSCT and were eligible for evaluation of
cGVHD.The2-year cumulative incidencesof cGVHD
in theHID and ISD cohorts were 62% (CI, 49%-75%)
and 39% (CI, 20%-58%), respectively (P 5 .11;
Figure 1B), with an RR of 1.52 (0.69-3.34) (P 5 .30;
Table 2).
Relapse
At last follow-up with a median of 12.3 months, 18
patients (22%) in the HID group and 17 patients
(47%) in the ISD group experienced leukemia relapse.
Two-year incidences of relapse for the HID and ISD
HSCT groups were 26% (15%-37%) and 49%
(31%-67%), respectively (P 5 .008; Figure 2A), with
Figure 1. Cumulative incidence of aGVHD (A) and cGVHD (B) after
ISD or HID HSCT (P 5 .014 and P 5 .11, respectively).
Table 2. Multivariate Analysis of aGVHD, cGVHD, TRM,
Relapse, and Survival
Outcome Hazard ratio (95% CI)* P
Myeloid engraftment
HID versus ISD 1.19 (0.75-1.91) .46
Platelet engraftment
HID versus ISD 0.73 (0.43-1.23) .23
Acute graft-versus-host disease
HID versus ISD 2.99 (1.25-7.21) .014
Other significant risk factors
ABO blood group .023†
Matched 1.00
Minor mismatched 0.88 (0.39-1.97) .75
Major mismatched 2.11 (1.17-3.80) .012
Chronic graft-versus-host disease
HID versus ISD 1.52 (0.69-3.34) .30
Nonrrelapse-related mortality
HID versus ISD 1.93 (0.85-4.37) .12
Relapse
HID versus ISD 0.21 (0.08-0.53) .001
Other significant risk factors
Diagnosis .002†
PH+ acute lymphoid leukemia 1.00
PH2 acute lymphoid leukemia 8.11 (2.38-27.63) .001
acute myelogenous leukemia 4.94 (1.81-13.52) .002
Overall survival
HID versus ISD 0.71 (0.37-1.36) .30
CI indicates confidence interval; ISD, identical sibling donors; HID,
haploidentical donors.
*The hazard ratio is for HID transplantation compared with ISD
transplantation.
†Two degrees of freedom test.
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In multivariate analysis, age was not a significant factor
influencing relapse rate, with a RR5 0.99 (P5 .57). In
patients with aGVHD, the relapse rates for the HID
and ISD HSCT groups were 23% and 13%, respec-
tively (P 5 .75). In patients without aGVHD, the
relapse rate for the HID and ISD HSCT groups were
26% and 59%, respectively (P 5 .002). In patients
with cGVHD, the relapse rate for the HID and
ISD HSCT groups were 22% and 36%, respectively
(P 5 .23). In patients without cGVHD, the relapse
rate for the HID and ISD HSCT groups were 22%
and 52%, respectively (P5 .027).
Eight of 30 patients with AML, 7 out of 16 with
PH-negative ALL, and 3 out of 35 with PH-positive
ALL relapsed after HID HSCT. Thirteen out of 20
with AML, 2 out of 3 with PH-negative ALL, and 2
out of 13 with PH-positive ALL relapsed after ISD
HSCT.Five patients received imatinib mesylate for treat-
ment of cytogenetic or hematologic relapse including
3 in the HID group and 2 in the ISD group. At the
time of last follow-up, 27 patients had died of relapse
including 14 in the HID group and 13 in the ISD
group, with a median time to death of 245 days (range:
34-790) and 284 days (range: 53-727) after HSCT, re-
spectively.NRM
Twopatients diedwithin 28 days ofHSCT, 1 in the
ISD group at day 18 because of heart failure, and an-
other in the HID group at day 24 because of infection.
Analyses of NRM are described in Table 3. Two-year
incidences ofNRM for theHID and ISDHCT groups
were 34% (22%-46%) and 38% (21%-55%), respec-
tively (P 5 .85; Figure 2B), with an RR 5 1.93 (CI,
0.85-4.37) (P 5 .12; Table 2). Nine patients (4 with
DLI, 5 without DLI) died beyond 1 year after
HSCT. Among the 9 patients, 3 patients in the ISD
group died at days 404, 524, and 572 because of infec-
tion. In theHIDgroup, 3 died at days 367, 478, and 690
from infection, 2 died at day 467 and 764 fromGVHD,
and 1 died at day 551 from organ failure.Long-Term Follow-Up and Survival
The 3-year overall survival (OS) after HCT was
42% (CI, 30%-54%) for HID patients and 20% (CI,
4%-36%) for ISD patients (P 5 .048). The 3-year
Figure 2. Cumulative incidence of relapse (A) and NRM (B) after ISD
or HID HSCT (P 5 .008 and P 5 .85, respectively).
Table 3. Causes of Death
Causes of Death ISD, n 5 26 HID, n 5 40
Relapse 13 (50) 14 (35)
Infection 10 (38) 22 (55)
Bacteria 4 9
Fungal 3 8
Viral 2 3
Unknown 1 2
GVHD 1 (4) 3 (7)
Organ failure 2 (8) 1 (3)
GVHD indicates graft-versus-host disease; ISD, identical sibling donors;
HID, haploidentical donors.
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15% in the ISD group (CI, 1%-29%) (P 5 .029;
Figure 3A-B).DISCUSSION
Some studies have shown that HLA disparity
might have a stronger GVL effect than ISD HSCT
[2,24]; however, conflicting data exist regarding this
issue [25,26]. Kanda et al. [2] reported that the cumu-
lative incidence of relapse was 22% after matched
HSCT for standard-risk diseases, which was not sig-
nificantly different from that after 1-locus–
mismatched HSCT (15%; P 5 .25). In contrast, the
incidence was 47% versus 19% (P 5 .004) for high-
risk diseases. Beatty et al. [24] reported that there
was a trend for the probability of relapse to be greater
in the matched unrelated group (23%) than in the par-
tially matched unrelated group (12%). Unrelated do-nor HSCT has comparable or lower relapse rate than
ISD HSCT [3,25]. Data from the International Bone
Marrow Transplant Registry (IBMTR) report
showed that 3-year probability of relapse was 13%
after 1-antigen–mismatched unrelated HSCT for
intermediate-stage diseases, which was not
significantly different from that after ISD HSCT
(29%; P 5 .10). In contrast, the incidence was 20%
versus 73% (P 5 .03) for advanced-stage diseases [3].
The present data show that the relapse rate for high-
risk patients after HID HSCT was lower than with
ISD HSCT. Data from our recent comparison be-
tween haploidentical and unrelated HSCT did not in-
dicate a significant difference for high-risk acute
leukemia patients because the small population of
high-risk patients in the unrelated group (18 patients)
made it difficult to demonstrate the difference. How-
ever, the 2-year probability of relapse for standard-
risk patients was 8% versus 19% (P 5 .033) in the
haploidentical and unrelated cohorts [16]. These ob-
servations indicate that HID HSCT might have
a stronger GVL effect than ISD HSCT.
Many factors can influence GVL and the relapse
rate after HSCT, such as disease type and remission
status before HSCT, T cell number infused, condi-
tioning regimen, GVHD prophylaxis, use of imatinib,
presence of aGVHD and cGVHD, patient age, and
other factors.
The composition of disease type was comparable
between the 2 study groups, with the exception that
the HID cohort comprised a larger proportion of
ALL patients (see Table 1). The GVL effect was gen-
erally weaker for ALL patients; however, in a larger
proportion of ALL patients in the HID cohort com-
pared to the ISD group, the relapse rate was still lower
for HID patients. For PH1-ALL patients, the suc-
cessful pre- or posttransplantation use of imatinib
[27,28] may reduce the incidence of relapse after
allo-HCT. However, in the current study, the propor-
tion of PH1-ALL patients (see Table 1) and the pro-
portion of patients receiving prophylactic imatinib
(P 5 .98) in the 2 cohorts were comparable.
All patients in this study were treated with similar
conditioning regimens without TCD. The 1 disparity
Figure 3. Probability of OS (A) and LFS (B) after ISD or HID HSCT
(P 5 .048 and P 5 .029, respectively).
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tients received ATG for additional immunosuppres-
sion. Although this is a distinguishing feature
between the groups, we do not believe that this affects
the interpretation of the data or the conclusions of the
study. The requirement for more intense immunosup-
pression in the haploidentical group is an integral as-
pect of the current treatment regimen for these
patients to prevent GVHD and to facilitate engraft-
ment [4]. It is unlikely that patients would be enrolled
in a study with an equivalent degree of immunosup-
pression between recipients of matched related grafts
and recipients of haploidentical grafts. Additionally,
the use of ATG to prevent GVHDwithout influencing
relapse [29,30] may make the GVL effect even weaker
[31]. Remberger [31] reported that the probabilities of
relapse were 41% and 27% with or without ATG as
part of conditioning after unrelatedHSCT. In patients
with CML in chronic phase (CP), the relapse probabil-ity was significantly higher in the ATG group (60%)
compared to the non-ATG cohort (18%; P 5 0.04).
Another disparity was that HID patients received
a higher dose of cytosine arabinoside (Ara-c). It is un-
likely that the lower relapse rate in the HID group was
attributed to the higher dose of Ara-c; however, this
variable cannot be completely excluded.
Numerous studies, including our own study,
showed that the presence of cGVHD is more impor-
tant than that of aGVHD for the GVL effect
[18,25,32]. In the current study, a higher incidence of
aGVHD occurred in haploidentical than in ISD
HSCT; however, in patients with aGVHD, the
relapse rates for the HID and ISD HSCT groups
were comparable (P 5 .75). In patients without
aGVHD, the relapse rates for the HID and ISD
HSCT groups were 26% and 59% (P 5 .002),
whereas in patients with cGVHD, the relapse rates
for the HID and ISD HSCT groups were
comparable (P 5 .23). In patients without cGVHD,
the relapse rates for the HID and ISD HSCT groups
were 22% and 52% (P 5 .027). This suggested
a GVL effect in the absence of GVHD, as confirmed
by HLA-identical sibling transplants without GVHD
having a reduced relapse risk compared with syngeneic
transplants [32].
Because of the 1-child policy in China, more than
half of our haploidentical donors were parents; thus, an
age difference existed between our 2 study groups (see
Table 1). Although younger patients tend to have bio-
logically less aggressive leukemia, our study popula-
tions were all high-risk patients, and in multivariate
analysis, age was not a significant factor affecting
relapse rate.
Although these potentially confounding factors
may play a role in the GVL effect, we believe that
under our general protocol, the lower incidence of
relapse in the HID group cannot be explained exclu-
sively by any of the factors discussed. Our data suggest
a superior antileukemia effect of HID without TCD
compared to ISD HSCT, at least for high-risk acute
leukemia patients. However, the biologic mechanism
needs to be further explored.
The engraftment rate and NRM were comparable
between the 2 study cohorts. In multivariate analysis,
there was a trend toward a higher risk of NRM among
recipients of haploidentical transplants compared to
ISD transplants (hazard ratio [HR] 1.93, P 5 .12),
whereas NRM was actually slightly lower among
recipients of haploidentical transplants. This result
may arise from the age difference between the 2 groups
because age was a significant factor affecting NRM in
multivariate analysis (data not shown). In a previous
comparative study reported by Lu et al. [33], NRM
for patients was comparable for ISD andHID patients,
with a 2-year NRM of 14% and 22%, respectively.
NRM in the current study was higher than in that
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in the current report. The proportion of high-risk pa-
tients in that previous report was 16% and 24% for
ISD and HID cohorts. Many studies, including our
own showed, that disease status can dramatically
affect NRM [3,14,15,34]. Data from the IBMTR
report showed that the 3-year NRM was 21%, 38%,
and 54%, respectively, for early-, intermediate-, and
advanced-stage diseases after ISDHSCT [3]. MacMil-
lan et al. [34] reported that 1 of the factors associated
with significantly worse 2-year TRM was a high-risk
diagnosis at the time of HCT (RR, 1.36; 95% CI,
1.07-1.73; P \ .01). In our 2006 report, the 2-year
NRM for haploidentical patients was 19.5% and
31.1%, respectively (similar to the current report), in
the standard-risk group and in the high-risk group
[14]. In our 2009 report, the 2-year NRM for haploi-
dentical acute leukemia patients in standard-risk and
high-risk groups was 18.6% and 30% for AML and
18.2% and 63.3% for ALL, respectively [15]. The
sets of transplanted patients between the current report
(from January 2005 to April 2009) and the previous re-
port by Lu et al. (from January 2002 to July 2004) were
not overlapping, but the difference in the NRM be-
tween the 2 studies cannot be explained by the trans-
plant year difference. Data from another comparative
study conducted by our group between January 2004
andDecember 2007 showed that theNRMwas similar
to the previous report by Lu et al. (20% and 18% after
HID and unrelated HSCT) [16]. Most of the sets of
transplanted patients between the previous report by
Lu et al. and that comparative study reported in 2009
were not overlapping, and the proportion of high-risk
patients was similar. NRM appears to have occurred
much later in the current report than in the previous re-
port by Lu et al. (Figure 2B). The primary cause for the
delayedNRM is described in theNRMResults section
stating that DLI may play a role for the delayed NRM.
A higher probability of survival was achieved for
HID patients in the current report. In the previous
comparative study reported by Lu et al. [33], survival
for patients with advanced disease was comparable
for ISD and HID patients, with 2-year probabilities
of survival of 45% and 47%, respectively. It appears
that the LFS in ISD patients in the current study was
inferior to that in the previous report. However, it
must be noted that previously, a smaller study popula-
tion (25 ISD and 32 HID patients), a different defini-
tion of high risk (apart from advanced or resistant AL,
also including myelodysplastic syndrome-refractory
anemia with excess blasts (MDS-RAEB) and chronic
myeloid leukemia-blastic phase (CML-BP), a hetero-
geneous series of patients (with a variety of diagnoses,
includingMDS andCML), and shorter follow-up time
for survival may have contributed to its better out-
comes. By contrast, the outcome of HLA-matched
transplantation in high-risk patients has remainedfairly constant at approximately 20% survival in
many other larger studies [2,3,25,29,35].
Considering the significantly lower relapse rate
and higher survival probability for HID patients than
for ISD patients, whether HID HSCT with ex vitro
T cell depletion should be selected instead of ISD
donors in patients with high-risk leukemia deserves
further evaluation.
In conclusion, the current study showed that
a lower relapse rate, a similar engraftment rate, and
a higher survival probability was achieved with HID
patients than with ISD patients. The results suggest
that HID HSCT might achieve a better antileukemia
effect for high-risk acute leukemia patients.ACKNOWLEDGMENTS
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